Wuhan Keqian Biology Co Ltd
SSE:688526
Wuhan Keqian Biology Co Ltd
SSE:688526
Price:
14.9
CNY
-2.17%
Market Closed
Market Cap:
¥6.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Wuhan Keqian Biology Co Ltd
SSE:688526
|
CN |
|
B
|
Bsm Chemical Co Ltd
SZSE:300796
|
CN |
|
APT Satellite Holdings Ltd
HKEX:1045
|
HK |
|
Surge Battery Metals Inc
XTSX:NILI
|
CA |
|
R
|
Runjian Co Ltd
SZSE:002929
|
CN |
|
C
|
Chanson International Holding
NASDAQ:CHSN
|
CN |
|
C
|
Clarus Corp
NASDAQ:CLAR
|
US |
|
I
|
I3 Verticals Inc
SWB:V1K
|
US |
|
J
|
Jutal Offshore Oil Services Ltd
HKEX:3303
|
CN |
|
G
|
Gaonchips Co Ltd
KOSDAQ:399720
|
KR |
|
E
|
Eft Solutions Holdings Ltd
HKEX:8062
|
HK |
|
Myomo Inc
F:0M61
|
US |
Multiples-Based Value
The Multiples-Based Value of one
Wuhan Keqian Biology Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 14.9 CNY,
Wuhan Keqian Biology Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Wuhan Keqian Biology Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Wuhan Keqian Biology Co Ltd Competitors
Wuhan Keqian Biology Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Wuhan Keqian Biology Co Ltd
SSE:688526
|
6.9B CNY | 6.8 | 15.1 | 12.9 | 12.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD | 2.5 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
